Literature DB >> 24597117

Protection and antibody response caused by turkey herpesvirus vector Newcastle disease vaccine.

Motoyuki Esaki1, Alecia Godoy1, Jack K Rosenberger2, Sandra C Rosenberger2, Yannick Gardin3, Atsushi Yasuda4, Kristi Moore Dorsey1.   

Abstract

Newcastle disease (ND) is prevalent worldwide and causes significant clinical and economic losses to the poultry industry. Current vaccine programs using live attenuated vaccines and inactivated vaccines have limitations, and new vaccines with distinct features are needed. To offer an alternative solution to control ND, a turkey herpesvirus vector Newcastle disease vaccine (HVT/ND) expressing the fusion gene of Newcastle disease virus (NDV) has been developed. First, immunogenicity of the HVT/ND was evaluated in specific-pathogen-free layer chickens after vaccination by the in ovo route to 18-day-old embryos or by the subcutaneous route to 1-day-old chicks. Antibodies against NDV were detected at 24 days of age using a commercial NDV enzyme-linked immunosorbent assay (ELISA) kit and the hemagglutination inhibition test. At least 90% of chickens were protected against challenge with velogenic neurotropic NDV Texas GB strain (genotype II; pathotype velogenic) at 4 wk of age, while none of the nonvaccinated, challenged controls were protected from challenge. Second, the age at which a vaccinated chicken elicits an immunologic response to the HVT/ND prepared for this study, and thus is protected from ND virus, was assessed in commercial broiler chickens after in ovo vaccination of 18-day-old embryos. Challenge was conducted using a low-virulence NDV strain (genotype II; pathotype lentogenic) via the respiratory tract each week between 1 and 5 wk of age, in order to mimic the situation in areas where virulent NDV strains do not normally exist and low-virulence strains cause mild respiratory symptoms leading to economic losses. Protection was evaluated by the presence or absence of isolated virus from tracheal swabs at 5 days postchallenge. Partial protection was observed at 3 wk of age, when 6 out of 10 (60%) chickens were protected. Full protection was obtained at 4 and 5 wk of age, when 9 out of 10 (90%) and 10 out of 10 (100%) chickens were protected, respectively. Finally, protection against challenge with virulent Texas GB strain at 19 wk of age was evaluated in commercial female layer chickens vaccinated at 1 day of age with HVT/ND. All of the vaccinated chickens were protected, while all of the challenge controls succumbed to the challenge. Furthermore, anti-NDV antibodies measured by ELISA were maintained through 50 wk of age.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24597117     DOI: 10.1637/10540-032613-Reg.1

Source DB:  PubMed          Journal:  Avian Dis        ISSN: 0005-2086            Impact factor:   1.577


  19 in total

1.  Genotype effect on distribution pattern of maternally derived antibody against Newcastle disease in Nigerian local chickens.

Authors:  Matthew Adekunle Adeleke; Sunday Olusola Peters; Dare Tunde Ogunmodede; Oluwole Oyetunde Oni; Olusola Lawrence Ajayi; Mathew Wheto; Olufunmilayo Ayoka Adebambo
Journal:  Trop Anim Health Prod       Date:  2014-12-30       Impact factor: 1.559

Review 2.  Diagnostic and Vaccination Approaches for Newcastle Disease Virus in Poultry: The Current and Emerging Perspectives.

Authors:  Muhammad Bashir Bello; Khatijah Yusoff; Aini Ideris; Mohd Hair-Bejo; Ben P H Peeters; Abdul Rahman Omar
Journal:  Biomed Res Int       Date:  2018-08-05       Impact factor: 3.411

3.  A Recombinant Turkey Herpesvirus Expressing F and HN Genes of Avian Avulavirus-1 (AAvV-1) Genotype VI Confers Cross-Protection against Challenge with Virulent AAvV-1 Genotypes IV and VII in Chickens.

Authors:  Krzysztof Śmietanka; Jolanta Tyborowska; Monika Olszewska-Tomczyk; Katarzyna Domańska-Blicharz; Zenon Minta; Lukasz Rabalski; Anna Czarnota; Krzysztof Kucharczyk; Boguslaw Szewczyk
Journal:  Viruses       Date:  2019-08-25       Impact factor: 5.048

Review 4.  Newcastle disease vaccines-A solved problem or a continuous challenge?

Authors:  Kiril M Dimitrov; Claudio L Afonso; Qingzhong Yu; Patti J Miller
Journal:  Vet Microbiol       Date:  2016-12-16       Impact factor: 3.293

5.  Infectious laryngotracheitis: Etiology, epidemiology, pathobiology, and advances in diagnosis and control - a comprehensive review.

Authors:  Vasudevan Gowthaman; Sachin Kumar; Monika Koul; Urmil Dave; T R Gopala Krishna Murthy; Palanivelu Munuswamy; Ruchi Tiwari; Kumaragurubaran Karthik; Kuldeep Dhama; Izabela Michalak; Sunil K Joshi
Journal:  Vet Q       Date:  2020-12       Impact factor: 3.320

6.  Experimental infection with Brazilian Newcastle disease virus strain in pigeons and chickens.

Authors:  Adriano de Oliveira Torres Carrasco; Meire Christina Seki; Jyan Lucas Benevenute; Priscila Ikeda; Aramis Augusto Pinto
Journal:  Braz J Microbiol       Date:  2016-01-27       Impact factor: 2.476

7.  The 3D8 single chain variable fragment protein suppresses Newcastle disease virus transmission in transgenic chickens.

Authors:  Sung June Byun; Hoonsung Choi; Shanmugam Sureshkumar; Seong-Su Yuk; Jung-Hoon Kwon; Jin-Yong Noh; Sun Keun Jung; Jeom Sun Kim; Keon Bong Oh; Hyeon Yang; Gunsup Lee; Hwi-Cheul Lee; Jae-Seok Woo; Chang-Seon Song
Journal:  BMC Vet Res       Date:  2020-08-06       Impact factor: 2.741

8.  Expression of Two Foreign Genes by a Newcastle Disease Virus Vector From the Optimal Insertion Sites through a Combination of the ITU and IRES-Dependent Expression Approaches.

Authors:  Lei He; Zhenyu Zhang; Qingzhong Yu
Journal:  Front Microbiol       Date:  2020-04-28       Impact factor: 5.640

9.  Isolation and molecular identification of wild Newcastle disease virus isolated from broiler farms of Diyala Province, Iraq.

Authors:  Amer Khazaal Alazawy; Karim Sadun Al Ajeeli
Journal:  Vet World       Date:  2020-01-04

10.  Chickens can durably clear herpesvirus vaccine infection in feathers while still carrying vaccine-induced antibodies.

Authors:  Sylvie Rémy; Gilles Le Pape; David Gourichon; Yannick Gardin; Caroline Denesvre
Journal:  Vet Res       Date:  2020-02-24       Impact factor: 3.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.